论文部分内容阅读
目的：探讨卵巢癌患者血清ＣＡ—１２５浓度的变化，为临床诊断治疗提供依据。方法：用免疫放射法分别对卵巢良、恶性肿瘤患者和健康女性血清进行ＣＡ—１２５测定。结果：卵巢癌患者血清ＣＡ—１２５浓度为２２１．０±５．３Ｕ／ｍｌ，良性卵巢肿瘤患者为９．５±２．４Ｕ／ｍｌ，健康女性为９．２±２．１Ｕ／ｍｌ。前者明显高于后二者（Ｐ＜０．０１）。１０例卵巢癌患者手术前后动态检测ＣＡ—１２５，其浓度降至正常水平的患者，症状明显好转，未见复发转移。术后血清ＣＡ—１２５浓度持续高水平或降至正常水平后又升高的患者，临床证实均存在复发或转移病灶，病情恶化。结论：ＣＡ—１２５测定可用于卵巢癌的辅助诊断，动态检测对术后卵巢癌的疗效观察、预后及复发的监测均有重要的价值
Objective: To investigate the changes of serum CA-125 concentration in ovarian cancer patients and provide evidence for clinical diagnosis and treatment. Methods: Serum CA-125 levels were measured in patients with ovarian benign and malignant tumors and healthy women by immunoradiotherapy. Results: Serum CA-125 concentration was 221.0±5.3 U/ml in patients with ovarian cancer, 9.5±2.4 U/ml in benign ovarian tumors and 9.2±2.1 U/ml in healthy women. The former was significantly higher than the latter two (P < 0.01). In 10 patients with ovarian cancer, CA-125 was dynamically detected before and after surgery. The concentration of CA125 was reduced to normal levels. Symptoms improved significantly and no recurrence or metastasis was found. Patients with elevated serum CA-125 levels or elevated to normal levels after surgery showed clinically confirmed recurrence or metastases and worsened disease. Conclusion: CA-125 can be used for the diagnosis of ovarian cancer. The dynamic detection has important value in the observation of the efficacy, prognosis and recurrence of ovarian cancer.